SEC Form S-8 filed by Gilead Sciences Inc.
$GILD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
As filed with the Securities and Exchange Commission on May 7, 2026
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
GILEAD SCIENCES, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 94-3047598 | |||||||
| (State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) | |||||||
333 Lakeside Drive
Foster City, California 94404
(Address of Principal Executive Offices, Zip Code)
Gilead Sciences, Inc. 2022 Equity Incentive Plan
(Full title of the plan)
Keeley M. Cain Wettan
Executive Vice President, General Counsel, Legal and Compliance, and Secretary
333 Lakeside Drive
Foster City, California 94404
(650) 574-3000
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copy to:
Ronald O. Mueller, Esq.
Gibson, Dunn & Crutcher LLP
1700 M Street, NW
Washington, DC 20036
(202) 955-8500
Gibson, Dunn & Crutcher LLP
1700 M Street, NW
Washington, DC 20036
(202) 955-8500
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | x | Accelerated filer | ¨ | ||||||||
| Non-accelerated filer | ¨ | Smaller reporting company | ¨ | ||||||||
| Emerging growth company | ¨ | ||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
EXPLANATORY NOTE
This Registration Statement on Form S-8 (this “Registration Statement”) is filed by Gilead Sciences, Inc. (the “Registrant”), relating to the registration of 47,750,000 shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), issuable to eligible persons under the Gilead Sciences, Inc. 2022 Equity Incentive Plan, as amended and restated.
The contents of the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on May 5, 2022 (File No. 333-264713), together with all exhibits filed therewith or incorporated therein by reference, are hereby incorporated by reference pursuant to General Instruction E to Form S-8, and the Common Stock registered hereunder are in addition to the Common Stock registered on such registration statement.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
| Item 8. | Exhibits. | ||||
| Exhibit No. | Exhibit Description | ||||
* Filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended (the “Securities Act”), the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Foster City, State of California, on May 7, 2026.
| GILEAD SCIENCES, INC. | |||||
| By: | /s/ DANIEL P. O’DAY | ||||
| Name: | Daniel P. O’Day | ||||
| Title: | Chairman and Chief Executive Officer | ||||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Daniel P. O’Day, Keeley M. Cain Wettan and Andrew D. Dickinson, and each of them, as the individual’s true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and any registration statement relating to the offering covered by this Registration Statement and filed pursuant to Rule 462(b) under the Securities Act, and to file the same, with exhibits thereto and other documents in connection therewith, with the Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitutes may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities indicated on the dates indicated.
| Signature | Title | Date | ||||||||||||
| /s/ DANIEL P. O’DAY | Chairman and Chief Executive Officer | May 7, 2026 | ||||||||||||
Daniel P. O’Day | (Principal Executive Officer) | |||||||||||||
| /s/ ANDREW D. DICKINSON | Chief Financial Officer | May 7, 2026 | ||||||||||||
Andrew D. Dickinson | (Principal Financial Officer) | |||||||||||||
| /s/ ERIN E. BURKHART | Senior Vice President, Controllership and Chief Accounting Officer | May 7, 2026 | ||||||||||||
Erin E. Burkhart | (Principal Accounting Officer) | |||||||||||||
| /s/ ANTHONY WELTERS | Lead Independent Director | May 7, 2026 | ||||||||||||
Anthony Welters | ||||||||||||||
| /s/ JACQUELINE K. BARTON | Director | May 7, 2026 | ||||||||||||
Jacqueline K. Barton, Ph.D. | ||||||||||||||
| /s/ JEFFREY A. BLUESTONE | Director | May 7, 2026 | ||||||||||||
Jeffrey A. Bluestone, Ph.D. | ||||||||||||||
| /s/ SANDRA J. HORNING | Director | May 7, 2026 | ||||||||||||
Sandra J. Horning, M.D. | ||||||||||||||
| /s/ KELLY A. KRAMER | Director | May 7, 2026 | ||||||||||||
Kelly A. Kramer | ||||||||||||||
| /s/ TED W. LOVE | Director | May 7, 2026 | ||||||||||||
| Ted W. Love, M.D. | ||||||||||||||
| /s/ HARISH MANWANI | Director | May 7, 2026 | ||||||||||||
Harish Manwani | ||||||||||||||
| /s/ JAVIER J. RODRIGUEZ | Director | May 7, 2026 | ||||||||||||
Javier J. Rodriguez | ||||||||||||||